Vaccines Europe is pleased to announce the integration of its first vaccine SME members in the association; Vaxeal and ImmBio. These two companies are research biotechs investing in the development of innovative therapeutic and prophylactic vaccines targeting unmet medical needs.
Vaccines Europe is the voice of the vaccine industry in Europe and aims to create a supportive environment for innovative vaccine delivery and improved vaccine protection. Integrating SMEs in the Vaccines Europe membership will enable it to strengthen its role as the representative of the vaccine industry, a strategic sector for public health worldwide and Europe’s competitiveness.
SMEs play a key role in bridging basic discoveries from academic research to clinical proof-of-concept, late stage development and product launch by larger companies. This calls for the need to boost and support the vaccine SME sector in Europe and encourage an innovation-friendly environment.
“This is a landmark step for Vaccines Europe, which represents a highly innovative and diverse global industry with a strong position in Europe. We hope to continue expanding this inclusion process throughout the year” – says Vaccines Europe President Andrea Rappagliosi – “Along with established players in the vaccine sector which have a track record of innovation, smaller companies are drivers of fresh ideas, and an important source of new jobs and economic growth in Europe”.